Patents by Inventor Erick Gamelin

Erick Gamelin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCER
    Publication number: 20210315991
    Abstract: The present disclosure describes combination therapies for breast cancer comprising an oligonucleotide toll-like receptor 9 agonist and a PD-1 antagonist. In particular, the present disclosure describes combinations of a CpG-C type oligonucleotide and an anti-PD-1 antibody for the treatment of breast cancer. The combination may further comprise a taxane chemotherapeutic agent, in the presence or absence of a corticosteroid.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Applicants: Surefire Medical, Inc. d/b/a TriSalus Life Sciences, The Regents of the University of California, H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Robert S. Janssen, Erick Gamelin, Laura J. Esserman, Amy Jo Chien, Hetem Soliman
  • Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
    Patent number: 9523691
    Abstract: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 20, 2016
    Assignee: INSTITUT DE CANCEROLOGIE DE L'OUEST
    Inventors: Catherine Guette, Olivier Coqueret, Benjamin Barre, Erick Gamelin
  • Individual 5-fluorouracile dose optimization in folfiri treatment
    Patent number: 9463193
    Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: October 11, 2016
    Assignees: INSTITUT DE CANCEROLOGIE DE L'OUEST, UNIVERSITE D'ANGERS
    Inventors: Erick Gamelin, Michéle Boisdron-Celle, Alain Morel
  • USE OF OLFACTOMEDIN-4 PROTEIN (OLFM4) IN COLORECTAL CANCER DIAGNOSIS
    Publication number: 20130336969
    Abstract: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
    Type: Application
    Filed: March 2, 2011
    Publication date: December 19, 2013
    Applicant: INSTITUT DE CANCEROLOGIE DE L'OUEST
    Inventors: Catherine Guette, Olivier Coqueret, Benjamin Barre, Erick Gamelin
  • INDIVIDUAL 5-FLUOROURACILE DOSE OPTIMIZATION IN FOLFOX TREATMENT
    Publication number: 20110246079
    Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFOX regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFOX or similar treatment cycle is optimized using the decision algorithm according to the invention.
    Type: Application
    Filed: September 26, 2008
    Publication date: October 6, 2011
    Inventors: Erick Gamelin, Michèle Boisdron-Celle, Alain Morel
  • INDIVIDUAL 5-FLUOROURACILE DOSE OPTIMIZATION IN FOLFIRI TREATMENT
    Publication number: 20110177092
    Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.
    Type: Application
    Filed: September 26, 2008
    Publication date: July 21, 2011
    Inventors: Erick Gamelin, Michèle Boisdron-Celle, Alain Morel
  • Protection against the neurotoxicity of oxaliplatin through the administration of calcium and magnesium
    Publication number: 20050148661
    Abstract: The invention relates to products comprising calcium, injectable magnesium and an injectable product which releases oxalate during the metabolism thereof as a combination that can be used for simultaneous, sequential or separate administration in anticancer and antiviral therapies.
    Type: Application
    Filed: January 14, 2003
    Publication date: July 7, 2005
    Applicant: Centre Regional de Lutte Contre le Cancer
    Inventors: Laurence Gamelin, Erick Gamelin, Michele Boisdron-Celle, Alain Morel